No Data
No Data
RBC Notes Updates on Bausch Xifaxan Patent Litigation With Norwich
Bausch Health announced updates in the Xifaxan patent litigation with Norwich, noting that both parties have filed petitions for panel rehearing or rehearing en banc in the Appellate Court. BHC expect
Bausch Health Shareholders Approve Key Proposals
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
LAVAL, Quebec, May 15, 2024– Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced the results of its 2024 annual meeting of shareholders.Annual Meeting ResultsThe 10 directors nominated at the
Bausch Health Defends XIFAXAN Patents Amid Litigation
Bausch Health: Norwich Seeks to Market Generic Version of Xifaxan 550 Mg Tablets to Treat Irritable Bowel Syndrome With Diarrhea in Adults >BHC
Bausch Health: Norwich Seeks to Market Generic Version of Xifaxan 550 Mg Tablets to Treat Irritable Bowel Syndrome With Diarrhea in Adults >BHC
Bausch Health Brief: Announcing Updates Related to Norwich XIFAXAN Matters
04:34 PM EDT, 05/14/2024 (MT Newswires) -- Bausch Health Brief: Announcing Updates Related to Norwich XIFAXAN Matters
Wolfboy : Yes